Loading stock…

Covivio (COV) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

COVCovivio

Revenue FY25$1.3B

GROWTH RATING↗

VERY WEAK3 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y-41%1

Revenue, next 3Y, CAGR-13%1

Revenue, next 5Y, CAGR-7%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-32%2

EPS growth, FY27E+2%4

EPS growth, FY28E+0%4

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Earnings are set to grow faster than sales (EPS about 0%/yr vs revenue -13%/yr), so margins should widen. One year dips: EPS falls 32% next year.

WEAKNESSES

Growth is the weak spot here, trailing 97% of companies worldwide.

Revenue is set to shrink 13%/yr over the next 3 years, behind most of the market.1/10

Revenue grew 6%/yr over the last 3 years, but it is set to shrink 13%/yr from here.

Over five years revenue is set to shrink 7%/yr, behind 90% of companies worldwide.1/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business heading into decline. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

COVCovivio

Total return Current−4.4%

Price return Current−43.0%

MOMENTUM RATING↗

VERY WEAK14 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-10%2

3-month return-16%2

YTD return-17%2

MID & LONG-TERM▾SCORE

% of 52-week high75%4

1-year return-15%3

3-year return+35%5

5-year return-15%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+35% over three years and -15% over five), roughly average for the market.

WEAKNESSES

It's down 15% over the past year, now 25% below its 52-week high. That is a touch behind the market.

The stock is underperforming over the past month (-10%), over three months (-16%) and so far this year (-17%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Covivio. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

COVCovivio

Revenue FY25$1.3B

GROWTH RATING↗

VERY WEAK3 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y-41%1

Revenue, next 3Y, CAGR-13%1

Revenue, next 5Y, CAGR-7%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-32%2

EPS growth, FY27E+2%4

EPS growth, FY28E+0%4

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Earnings are set to grow faster than sales (EPS about 0%/yr vs revenue -13%/yr), so margins should widen. One year dips: EPS falls 32% next year.

WEAKNESSES

Growth is the weak spot here, trailing 97% of companies worldwide.

Revenue is set to shrink 13%/yr over the next 3 years, behind most of the market.1/10

Revenue grew 6%/yr over the last 3 years, but it is set to shrink 13%/yr from here.

Over five years revenue is set to shrink 7%/yr, behind 90% of companies worldwide.1/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business heading into decline. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

COVCovivio

Total return Current−4.4%

Price return Current−43.0%

MOMENTUM RATING↗

VERY WEAK14 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-10%2

3-month return-16%2

YTD return-17%2

MID & LONG-TERM▾SCORE

% of 52-week high75%4

1-year return-15%3

3-year return+35%5

5-year return-15%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+35% over three years and -15% over five), roughly average for the market.

WEAKNESSES

It's down 15% over the past year, now 25% below its 52-week high. That is a touch behind the market.

The stock is underperforming over the past month (-10%), over three months (-16%) and so far this year (-17%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Covivio. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Covivio

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Covivio. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Covivio. Get the full investment case.

Premium